STOCK COMMENTS / EPS CHANGESBlackRock ( BLK) target raised at Jefferies t o $198, Jefferies said. ETF fee cuts less than feared. Hold rating. Citigroup ( C) estimates, target boosted at JMP. Shares of C now seen reaching $26, according to JMP Securities. Estimates also upped, given higher expected mortgage production. Underperform rating. Clean Harbors ( CLH) estimates, target cut at JP Morgan. CLH estimates were reduced through 2013, JP Morgan said. Company is leveraged to bad weather and lower rental equipment usage. Overweight rating and new $65 price target. Costco ( COST) estimates, target raised at Guggenheim. Shares of COST now seen reaching $98, according to Guggenheim. Estimates also increased, as the company is cutting costs and seeing higher membership income. Discovery ( DISCA) estimates, target increased at Lazard. DISCA estimates were raised through 2013, Lazard said. Company can continue to deliver above-average audience growth. Buy rating and new $77 price target. Gannett ( GCI) numbers raised at UBS. Shares of GCI now seen reaching $19, UBS said. Estimates also raised on strong publishing / broadcast. Neutral rating. Microchip Technology ( MCHP) numbers lowered at Jefferies. Shares of MCHP now seen reaching $38, Jefferies said. Estimates also lowered on negative pre-announcement. Buy rating. Microchip estimates, target cut at Credit Suisse. Shares of MCHP now seen reaching $38, according to Credit Suisse. Estimates also reduced, given the company's new guidance. Outperform rating. Microsoft ( MSFT) estimates, target cut at MKM. Shares of MSFT now seen reaching $32, according to MKM Partners. Estimates also reduced, Company is seeing slower Windows growth. Neutral rating. NetApp ( NTAP) target cut at UBS to $40.50, UBS said. Inexpensive, but faces long term challenges. Buy rating. Sirius XM ( SIRI) added to US 1 List at BofA/Merrill. Company can deliver solid, visible and predictable operating growth. Tenneco ( TEN) numbers lowered at Jefferies. T Shares of TEN now seen reaching $34, Jefferies said. Estimates also lowered on weakness in Global CV and Europe. Buy rating. Teva ( TEVA) estimates, target reduced at Canaccord. TEVA estimates were cut through 2013, Canaccord Genuity said. Company is facing a lower US generic outlook. Buy rating and new $50 price target. >To submit a news tip, email: firstname.lastname@example.org.
Twitter and become a fan on Facebook.